[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636185":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":34,"centralContacts":38,"locations":43,"responsibleParty":92,"collaborators":20,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":20,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":20,"enrollmentInfo":103,"targetDuration":20,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":117,"whyStopped":20,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Participants randomized to the intervention arm will receive a light-touch, multi-modal medication adherence support package, including a one-time educational video, a symptom monitoring card, and weekly one-way text message reminders.",[13,14,15],"Behavioral: Educational video","Behavioral: Symptom monitoring card","Behavioral: Text reminders",{"label":17,"type":18,"description":19,"interventionNames":20},"Control","NO_INTERVENTION","Participants will receive standard care.",null,[22,27,30],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":20},"BEHAVIORAL","Educational video","One-time educational video",[9],{"type":23,"name":28,"description":28,"armGroupLabels":29,"otherNames":20},"Symptom monitoring card",[9],{"type":23,"name":31,"description":32,"armGroupLabels":33,"otherNames":20},"Text reminders","Weekly one-way text reminders",[9],[35],{"name":36,"affiliation":5,"role":37},"Temidayo Fadelu, MD","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":20,"email":42},"CONTACT","617-632-3779","temidayo_fadelu@dfci.harvard.edu",[44,60,69,77],{"facility":45,"status":20,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Brigham and Women's Hospital","Boston","Massachusetts","02053","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-71.05977,42.35843,{"lat":55,"lon":54},[58,59],{"name":36,"role":40,"phone":41,"phoneExt":20,"email":42},{"name":36,"role":37,"phone":20,"phoneExt":20,"email":20},{"facility":61,"status":20,"city":46,"state":47,"zip":62,"country":49,"countryCode":50,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Boston Children's Hospital","02115",{"type":52,"coordinates":64},[54,55],{"lat":55,"lon":54},[67,68],{"name":36,"role":40,"phone":41,"phoneExt":20,"email":42},{"name":36,"role":37,"phone":20,"phoneExt":20,"email":20},{"facility":5,"status":20,"city":46,"state":47,"zip":70,"country":49,"countryCode":50,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"02215",{"type":52,"coordinates":72},[54,55],{"lat":55,"lon":54},[75,76],{"name":36,"role":40,"phone":41,"phoneExt":20,"email":42},{"name":36,"role":37,"phone":20,"phoneExt":20,"email":20},{"facility":78,"status":20,"city":79,"state":80,"zip":48,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Butaro Cancer Center of Excellence","Butaro","RN8","Rwanda","RW",{"type":52,"coordinates":84},[85,86],29.8313,-1.4079,{"lat":86,"lon":85},[89,91],{"name":36,"role":40,"phone":90,"phoneExt":20,"email":42},"2406608885",{"name":36,"role":37,"phone":20,"phoneExt":20,"email":20},{"type":37,"investigatorFullName":36,"investigatorTitle":93,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator","100636185","adjuvant-endocrine-therapy-adherence-intervention-pilot-in-rwanda-100636185",false,"NCT07562399","Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda","Piloting an Intervention to Improve Adjuvant Endocrine Therapy Adherence in Patients With Breast Cancer in Rwanda","Inclusion Criteria:\n\n* Female patients\n* Age 18 or older\n* Pathologic confirmation of ER-positive breast cancer\n* Clinical or radiographic confirmation of disease localized to the breast and regional lymph nodes\n* Within 6-36 months of starting AET\n* Have a cellphone capable of receiving text messages.\n* Are currently receiving AET at Butaro or satellite clinics.\n\nExclusion Criteria:\n\n* Unwilling\u002FUnable to participate\n* Unable to comprehend study languages (English or Kinyarwanda)\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Pregnant women","FEMALE","18 Years",{"count":104,"type":105},224,"ESTIMATED","INTERVENTIONAL",[108],"NA","This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda. The intervention includes educational, behavioral, and reminder components, and will be assessed for feasibility and impact on medication adherence.",[111,112],"Medication Adherence","Breast Cancer",[114,115,116],"breast cancer","medication adherence","ER-positive breast cancer","NOT_YET_RECRUITING","2026-05-18",{"date":120,"type":121},"2026-05-20","ACTUAL",{"date":123,"type":105},"2026-09-20",{"date":125,"type":105},"2028-12-31",{"name":5,"class":6},4]